BioPharma Resources

Drug Trial Radar · NCT06508983

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jun 14, 2024

Primary completion

Mar 31, 2027

Study completion Mar 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • SG301 InjectionDrug

    Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

  • SG301 placeboDrug

    Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

  • pomalidomideDrug

    Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.

  • dexamethasoneDrug

    Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (stage 1)Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
  2. Recommended stage 2 dose of SG301 (Stage 1)Time frame: Up to approximately 6 months.
  3. Progression Free Survival (Stage 2)Time frame: From baseline through the end of study. Assessed every 4 weeks after randomization until C19D1, and every 8 weeks thereafter until disease progression (IMWG criteria) or death whichever occurs first, assessed up to approximately 4 years.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital of Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital Of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Shanxi Provincial Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)

    Xi’an, Shanxi, China · Recruiting

  • Tianjin Cancer University Airport Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The Second Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.